Perinatal psychiatry for the paediatrician on the postnatal ward

Published:November 25, 2021DOI:https://doi.org/10.1016/j.paed.2021.10.006

      Abstract

      Maternal health and wellbeing is crucial to ensure the best outcomes for babies and children. Pregnancy and the perinatal period are particularly vulnerable times for mothers and children. Almost 1 in 5 mothers will experience some form of depression or anxiety during the perinatal period and other presentations, such as postpartum psychosis are specific to this period. Healthcare professionals, including paediatricians, whose clinical practice is devoted to the care of children often feel inadequately prepared to deal with these issues. Perinatal mental illnesses can feel daunting with anxiety about treatment impacting on the developing fetus, neonate or the breastfeeding infant. This short paper covers some common perinatal psychiatric presentations and aspects of treatment relevant for paediatricians.

      Keywords

      To read this article in full you will need to make a payment

      References

        • McAllister-Williams
        • Baldwin D.
        • Cantwell R.
        • et al.
        British Association for Psychopharmacology consensus on the use of psychotropic medication preconception in pregnancy and postpartum 2017.
        J Psychopharmacol. 2017; 31: 519-552
      1. NICE guideline CG192 Antenatal and postnatal mental health: clinical management and service guideline https://www.nice.org.uk/guidance/cg192.

      2. FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns: https://www.fda.gov/drugs/drugsafety/ucm243903.htm.

      Further reading

        • Campbell E.
        • Kennedy F.
        • Russel A.
        • et al.
        Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers.
        J Neurol Neurosurg Psychiatr. 2014; 85: 9
        • Chambers C.D.
        • Hernandez-Diaz S.
        • Van Marter L.J.
        • et al.
        Selective-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.
        N Engl J Med. 2006; 354: 579-587
        • Cohen L.
        • Viguera A.
        • McInerney K.
        • et al.
        Reproductive safety of second generation antipsychotics: current data from the Massachusetts general hospital national pregnancy registry for atypical antipsychotics.
        Am J Psychiatr. 2016; 173: 263-270
        • Cohen-Israel
        • Berger I.
        • Martinovich E.
        • Klinger G.
        • Stahl B.
        • Linder N.
        Short and long-term complications of in utero exposure to lamotrigine.
        Br J Clin Pharmacol. 2018; 84: 189-194
        • Huybrechts K.
        • Hernandez-Diaz S.
        • Parterno E.
        • et al.
        Antipsychotic use in pregnancy and the risk of congenital malformations.
        JAMA Psychiatry. 2016 Sep 1; 73: 938-946
        • Huybrechts
        • Bateman B.
        • Hernandez S.
        • et al.
        Risk of neonatal drug withdrawal after intrauterine co-exposure to opoids and psychotropic medications: cohort study.
        BMJ. 2017; 358: j3326
        • Lauren M.
        • Osbourne M.D.
        Recognizing and managing postpartum psychosis: a clinical guide for obstetric providers.
        Obstet Gynecol Clin N Am. 2018; 45: 455-468
        • Macfarlane Alastair
        • Greenhalgh Trisha
        Sodium valproate in pregnancy: what are the risks and should we use a shared decision-making approach?.
        BMC Pregnancy Childbirth. 1 Jun. 2018; 18: 1